Document Detail

Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.
MedLine Citation:
PMID:  20556668     Owner:  NLM     Status:  MEDLINE    
A decade has passed since the discovery of angiotensin-converting enzyme 2 (ACE2), a component of the ACE2-angiotensin (Ang)-(1-7)-Mas counterregulatory axis of the renin angiotensin system (RAS). ACE2 is considered an endogenous regulator of the vasoconstrictive, proliferative, fibrotic, and proinflammatory effects of the ACE-Ang II-angiotensin II type 1 receptor (AT(1)R) axis. Both animal and clinical studies have emerged to define a role for ACE2 in pulmonary arterial hypertension (PAH). There is scientific evidence supporting the concept that ACE2 maintains the RAS balance and plays a protective role in PAH. The activation of pulmonary ACE2 could influence the pathogenesis of PAH and serve as a novel therapeutic target in PAH. Current therapeutic strategies and interventions have limited success, and PAH remains a fatal disease. Thus, more research that establishes the novel therapeutic potential and defines the mechanism of the ACE2-Ang-(1-7)-Mas counterregulatory axis in PAH is needed.
Chastity N Bradford; Debra R Ely; Mohan K Raizada
Related Documents :
19335748 - Bleeding events in pulmonary arterial hypertension.
9719018 - Systemic hypertension and coronary artery disease.
487838 - Structural rebuilding of pulmonary vessels at various haemodynamic shifts in the lesser...
17344658 - Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragma...
15482028 - A novel technique of aortomonoiliac aaa repair in patients with a single patent iliac a...
7303048 - Transient ischemic attacks and external carotid artery. a retrospective study of 23 pat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  12     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-28     Completed Date:  2011-06-02     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  212-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Cardiovascular Diseases / prevention & control
Hypertension, Pulmonary / drug therapy*,  physiopathology
Lung Diseases / drug therapy
Peptidyl-Dipeptidase A / drug effects*
Renin-Angiotensin System / drug effects*
Signal Transduction / drug effects
Grant Support
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; EC A; EC 3.4.17.-/angiotensin converting enzyme 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.
Next Document:  Alterations of cortical GABA neurons and network oscillations in schizophrenia.